These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 31684193)

  • 21. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer.
    Zhao R; Cai Z; Li S; Cheng Y; Gao H; Liu F; Wu S; Liu S; Dong Y; Zheng L; Zhang W; Wu X; Yao X
    Oncotarget; 2017 Feb; 8(6):9293-9302. PubMed ID: 28030836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. S-Nitrosocaptopril prevents cancer metastasis in vivo by creating the hostile bloodstream microenvironment against circulating tumor cells.
    Lu Y; Lian S; Ye Y; Yu T; Liang H; Cheng Y; Xie J; Zhu Y; Xie X; Yu S; Gao Y; Jia L
    Pharmacol Res; 2019 Jan; 139():535-549. PubMed ID: 30366102
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EMT, CTCs and CSCs in tumor relapse and drug-resistance.
    Mitra A; Mishra L; Li S
    Oncotarget; 2015 May; 6(13):10697-711. PubMed ID: 25986923
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epithelial-Mesenchymal Plasticity in Circulating Tumor Cells, the Precursors of Metastasis.
    Burr R; Gilles C; Thompson EW; Maheswaran S
    Adv Exp Med Biol; 2020; 1220():11-34. PubMed ID: 32304077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathology of circulating tumor cells and the available capture tools (Review).
    Guan Y; Xu F; Tian J; Chen H; Yang C; Huang S; Gao K; Wan Z; Li M; He M; Chong T
    Oncol Rep; 2020 May; 43(5):1355-1364. PubMed ID: 32323847
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current progress in the clinical use of circulating tumor cells as prognostic biomarkers.
    Jin KT; Chen XY; Lan HR; Wang SB; Ying XJ; Abdi SM; Wang W; Hu ZM; Mou XZ
    Cancer Cytopathol; 2019 Dec; 127(12):739-749. PubMed ID: 31589381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phenotype of circulating tumor cell: face-off between epithelial and mesenchymal masks.
    Hong Y; Zhang Q
    Tumour Biol; 2016 May; 37(5):5663-74. PubMed ID: 26758432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Future of circulating tumor cells in the melanoma clinical and research laboratory settings.
    De Souza LM; Robertson BM; Robertson GP
    Cancer Lett; 2017 Apr; 392():60-70. PubMed ID: 28163189
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
    Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
    BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Metastasis: new functional implications of platelets and megakaryocytes.
    Leblanc R; Peyruchaud O
    Blood; 2016 Jul; 128(1):24-31. PubMed ID: 27154188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mesenchymal circulating tumor cells (CTCs) and OCT4 mRNA expression in CTCs for prognosis prediction in patients with non-small-cell lung cancer.
    Li S; Chen Q; Li H; Wu Y; Feng J; Yan Y
    Clin Transl Oncol; 2017 Sep; 19(9):1147-1153. PubMed ID: 28374320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genetic engineering of platelets to neutralize circulating tumor cells.
    Li J; Sharkey CC; Wun B; Liesveld JL; King MR
    J Control Release; 2016 Apr; 228():38-47. PubMed ID: 26921521
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular Characterization of Circulating Tumor Cells to Study Cancer Immunoevasion.
    Nicolazzo C; Gradilone A; Carpino G; Gazzaniga P; Raimondi C
    Methods Mol Biol; 2019; 1884():247-258. PubMed ID: 30465208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating and disseminated tumor cells: harbingers or initiators of metastasis?
    Dasgupta A; Lim AR; Ghajar CM
    Mol Oncol; 2017 Jan; 11(1):40-61. PubMed ID: 28085223
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modalities to enumerate circulating tumor cells in the bloodstream for cancer prognosis and to monitor the response to the therapy.
    Romano G
    Drugs Today (Barc); 2017 Sep; 53(9):501-514. PubMed ID: 29238763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibronectin Regulation of Integrin B1 and SLUG in Circulating Tumor Cells.
    Huaman J; Naidoo M; Zang X; Ogunwobi OO
    Cells; 2019 Jun; 8(6):. PubMed ID: 31226820
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A conduit to metastasis: circulating tumor cell biology.
    Micalizzi DS; Maheswaran S; Haber DA
    Genes Dev; 2017 Sep; 31(18):1827-1840. PubMed ID: 29051388
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunosuppressive cells in tumor immune escape and metastasis.
    Liu Y; Cao X
    J Mol Med (Berl); 2016 May; 94(5):509-22. PubMed ID: 26689709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An improved strategy to detect the epithelial-mesenchymal transition process in circulating tumor cells in hepatocellular carcinoma patients.
    Liu YK; Hu BS; Li ZL; He X; Li Y; Lu LG
    Hepatol Int; 2016 Jul; 10(4):640-6. PubMed ID: 27115761
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.